Albumin and interferon-β fusion protein serves as an effective vaccine adjuvant to enhance antigen-specific CD8+ T cell-mediated antitumor immunity.

Ssu-Hsueh TsengMax A ChengEmily FarmerLouise FerrallYu Jui KungBrandon LamLing LimT-C WuChien Fu Hung

Published in: Journal for immunotherapy of cancer (2022)

Overall, Alb-IFNβ serves as a potent adjuvant for enhancement of strong antigen-specific CD8 +T cell antitumor immunity, reduction of tumor burden, and increase in overall survival. Alb-IFNβ potentially can serve as an innovative adjuvant for the development of vaccines for the control of infectious disease and cancer.

Keyphrases

early stage
dendritic cells
infectious diseases
immune response
papillary thyroid
childhood cancer